{"id":"ly01011","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LY01011 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It also suppresses glucagon secretion and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. The extended half-life formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists.","oneSentence":"LY01011 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:51.175Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04859569","phase":"PHASE3","title":"Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors","status":"UNKNOWN","sponsor":"Luye Pharma Group Ltd.","startDate":"2021-04-30","conditions":"Bone Metastases From Solid Tumors","enrollment":850},{"nctId":"NCT04198636","phase":"PHASE1","title":"A Study to Evaluate LY01011 and Xgeva® in Healthy Adults","status":"UNKNOWN","sponsor":"Luye Pharma Group Ltd.","startDate":"2019-12-16","conditions":"Healthy Adults","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["recombinant anti-RANKL human monoclonal antibody injection","subcutaneous injection of 120 mg (1.7 ml)"],"phase":"phase_3","status":"active","brandName":"LY01011","genericName":"LY01011","companyName":"Luye Pharma Group Ltd.","companyId":"luye-pharma-group-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY01011 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}